News | April 30, 2015

FDA Warns of Mammography Quality Issues at California Facility

Patients who received mammograms between Feb. 24, 2013, and Feb. 24, 2015, advised to follow up with their healthcare professionals

FDA, ACR, mammography quality, Coastal Diagnostic Center

April 30, 2015 — The U.S. Food and Drug Administration (FDA) is alerting patients who had mammograms at Coastal Diagnostic Center in Pismo Beach, California, on or after Feb. 24, 2013, about possible problems with the quality of their mammograms. This does not mean that the results of the mammograms were inaccurate, but it does mean that the patients should consider having their mammograms re-evaluated at a Mammography Quality Standards Act (MQSA)-certified facility to determine if they need a repeat mammogram or additional medical follow-up.

The FDA became aware of problems following an American College of Radiology (ACR) clinical image review of mammograms performed at the facility between Feb. 24, 2013, and Feb. 24, 2015. The review was conducted after deficiencies were noted in the clinical cases that were submitted with the facility’s accreditation renewal application. The ACR revoked the facility’s accreditation effective April 10, 2015.

On April 24, the FDA required the facility to notify all patients who received mammograms at Coastal Diagnostic Center during the specified period, and their referring healthcare providers, about the problems with the mammography quality at the facility.

Under the MQSA of 1992, the FDA requires that all mammography facilities meet certain baseline quality standards and be certified to legally operate in the United States. This facility did not meet standards for mammography quality under the Act. The facility may no longer legally perform mammography at this time due to the revocation of its accreditation by the ACR and its MQSA certification being no longer in effect.

The FDA recommends the following actions:

  • If you have had a more recent mammogram at a MQSA-certified facility since then, you should follow the recommendations from that facility.
  • If you have not had a mammogram at an MQSA-certified facility since then, follow these guidelines:
    • Talk with your healthcare provider as soon as possible about the need for a follow-up exam
    • If your healthcare provider recommends a repeat mammogram, it should be done at an MQSA-certified facility to ensure quality and accuracy.

For more information: www.fda.gov

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

Feature | Breast Imaging | July 03, 2019 | By Greg Freiherr
Productivity and its enabler — efficiency — guided the display of products at the April...
Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine
Feature | Women's Health | July 03, 2019 | By Samir Parikh
Contrary to what many people believe,...

Image courtesy of GE Healthcare

Feature | Radiology Business | July 03, 2019 | By Jeffrey Hoffmeister, M.D.
Burnout in the medical profession is not uncommon, particularly as clinicians have become more overwhelmed by growing
iCAD ProFound AI

Image courtesy of iCAD

News | Breast Imaging | June 25, 2019
Use of...